MX2008015899A - Procedimiento para hacer sales de n-hidroxi-3-[4-[[[2-(2-metil-1h- indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida. - Google Patents

Procedimiento para hacer sales de n-hidroxi-3-[4-[[[2-(2-metil-1h- indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida.

Info

Publication number
MX2008015899A
MX2008015899A MX2008015899A MX2008015899A MX2008015899A MX 2008015899 A MX2008015899 A MX 2008015899A MX 2008015899 A MX2008015899 A MX 2008015899A MX 2008015899 A MX2008015899 A MX 2008015899A MX 2008015899 A MX2008015899 A MX 2008015899A
Authority
MX
Mexico
Prior art keywords
methyl
propenamide
hydroxy
phenyl
ethyl
Prior art date
Application number
MX2008015899A
Other languages
English (en)
Inventor
Joel Slade
David John Parker
Joginder S Bajwa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832680&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008015899(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2008015899A publication Critical patent/MX2008015899A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A través de varios métodos se preparan sales de N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)etil]amino]metil]fenil ]-2E-2-propenamida.
MX2008015899A 2006-06-12 2007-06-07 Procedimiento para hacer sales de n-hidroxi-3-[4-[[[2-(2-metil-1h- indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida. MX2008015899A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80452906P 2006-06-12 2006-06-12
US85325906P 2006-10-20 2006-10-20
PCT/US2007/070562 WO2007146717A2 (en) 2006-06-12 2007-06-07 Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Publications (1)

Publication Number Publication Date
MX2008015899A true MX2008015899A (es) 2009-04-01

Family

ID=38832680

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008015899A MX2008015899A (es) 2006-06-12 2007-06-07 Procedimiento para hacer sales de n-hidroxi-3-[4-[[[2-(2-metil-1h- indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida.

Country Status (24)

Country Link
US (1) US7989639B2 (es)
EP (1) EP2032532B8 (es)
JP (1) JP2009540007A (es)
KR (1) KR20090026282A (es)
AR (1) AR061295A1 (es)
AU (1) AU2007257882B2 (es)
BR (1) BRPI0713653A2 (es)
CA (1) CA2654230C (es)
CL (1) CL2007001690A1 (es)
EC (1) ECSP088957A (es)
GT (1) GT200800281A (es)
HK (1) HK1126495A1 (es)
IL (1) IL195344A (es)
JO (1) JO3099B1 (es)
MA (1) MA30564B1 (es)
MX (1) MX2008015899A (es)
MY (1) MY147013A (es)
NO (1) NO20090136L (es)
NZ (1) NZ572744A (es)
PE (1) PE20080365A1 (es)
RU (1) RU2008151724A (es)
TN (1) TNSN08508A1 (es)
TW (1) TWI385142B (es)
WO (1) WO2007146717A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009540005A (ja) * 2006-06-12 2009-11-19 ノバルティス アクチエンゲゼルシャフト Ｎ−ヒドロキシ−３−［４−［［［２−（２−メチル−１ｈ−インドール−３−イル）エチル］アミノ］メチル］フェニル］−２ｅ−２−プロペンアミドの塩
ES2553255T3 (es) * 2006-06-12 2015-12-07 Novartis Ag Procedimiento para fabricar materiales de partida para N-hidroxi-3-[4-[2-(2-metil-1H-indol-3-il)-etilaminometil]-fenil]-2E-2-propenamida
US20100292291A1 (en) * 2007-01-10 2010-11-18 Thitiwan Buranachokpaisan Formulations of deacetylase inhibitors
JP5485138B2 (ja) * 2008-03-28 2014-05-07 浜理薬品工業株式会社 エチニルチミジン化合物の精製方法
EP3077375B1 (en) * 2013-12-02 2017-07-19 Suven Life Sciences Limited Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate
WO2017221163A1 (en) * 2016-06-21 2017-12-28 Alembic Pharmaceuticals Limited Novel salts and polymorphic forms of panobinostat
WO2018092151A1 (en) * 2016-11-21 2018-05-24 Msn Laboratories Private Limited, R&D Center Process for the preparation of 2-(e)-n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl) ethyl]amino]methyl]phenyl]-2-propenamide 2-hydroxypropanoic acid (1:1) and its polymorphs thereof
WO2018163114A1 (en) * 2017-03-10 2018-09-13 Shilpa Medicare Limited Amorphous panobinostat and its lactate salt
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US20230416255A1 (en) * 2022-06-27 2023-12-28 Abion Inc. Mesylate salts of triazolopyrazine derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH342565A (de) 1954-04-14 1959-11-30 Thomae Gmbh Dr K Verfahren zur Herstellung von basischen Äthern endocyclisch substituierter Carbinole oder ihren nicht quaternären Salzen
GB891413A (en) 1958-10-06 1962-03-14 Smith Kline French Lab Tris-(dialkylaminoalkyl) phosphates and a method for their preparation
GB8600397D0 (en) 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60215028T2 (de) * 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
PT1443967E (pt) * 2001-11-06 2007-04-30 Novartis Ag Combinação de inibidor da ciclooxigenase-2/inibidor da histona-desacetilase
US20040224952A1 (en) * 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
CA2562627A1 (en) * 2004-04-26 2005-11-10 Santiago Ini Preparation of tegaserod and tegaserod maleate
TW200613275A (en) 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts

Also Published As

Publication number Publication date
ECSP088957A (es) 2009-01-30
NZ572744A (en) 2011-05-27
CL2007001690A1 (es) 2008-05-16
US7989639B2 (en) 2011-08-02
TNSN08508A1 (en) 2010-04-14
WO2007146717A3 (en) 2008-03-27
IL195344A0 (en) 2009-08-03
IL195344A (en) 2014-11-30
GT200800281A (es) 2009-03-18
CA2654230C (en) 2012-09-11
NO20090136L (no) 2009-03-06
TW200808692A (en) 2008-02-16
US20090187029A1 (en) 2009-07-23
AR061295A1 (es) 2008-08-20
HK1126495A1 (en) 2009-09-04
MY147013A (en) 2012-10-15
PE20080365A1 (es) 2008-05-07
JO3099B1 (ar) 2017-03-15
JP2009540007A (ja) 2009-11-19
WO2007146717A2 (en) 2007-12-21
CA2654230A1 (en) 2007-12-21
RU2008151724A (ru) 2010-07-20
AU2007257882A1 (en) 2007-12-21
EP2032532B8 (en) 2015-07-01
AU2007257882B2 (en) 2011-09-08
EP2032532B1 (en) 2015-04-22
TWI385142B (zh) 2013-02-11
MA30564B1 (fr) 2009-07-01
BRPI0713653A2 (pt) 2012-10-23
KR20090026282A (ko) 2009-03-12
EP2032532A2 (en) 2009-03-11

Similar Documents

Publication Publication Date Title
MX2008015899A (es) Procedimiento para hacer sales de n-hidroxi-3-[4-[[[2-(2-metil-1h- indol-3-il)etil]amino]metil]fenil]-2e-2-propenamida.
MY149337A (en) Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
JO3138B1 (ar) املاح n- هيدروكسي -3- [4-[[[2-(2-مثيل-h1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e2-2-بروبيناميد
ZA200809651B (en) Process for making salts of N-hydroxy-3[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
UA95289C2 (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
UA97243C2 (en) Crystalline anhydrous form of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
TNSN08507A1 (en) Process for making n-hydroxy -3- [4-[[[2-(2-metyl -1h- indol -3- yl) ethyl] amino] methyl]phenyl] -2e -2- propenamide and starting materials therefor
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
DOP2008000069A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.

Legal Events

Date Code Title Description
FG Grant or registration